Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2018
Price : $35 *
At a glance
- Drugs Imatinib (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 31 Aug 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 20 Jun 2017 Planned End Date changed from 1 Sep 2019 to 1 Sep 2018.